Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0606 • ACR Convergence 2022
Mechanism of Joint-Specific Homeobox D10 Regulation in Rheumatoid Arthritis Fibroblast-Like Synoviocytes
Hyeonjeong Lee¹, Camilla Machado², Deepa Hammaker³, Wei Wang⁴, David Boyle⁵ and Gary S. Firestein⁶, ¹University of California San Diego, San Diego, CA, ²UCSD, San Diego, CA, ³UC San Diego, San Diego, CA, CA, ⁴University of California San Diego, San Diego, ⁵UCSD, La Jolla, CA, ⁶University of California, San Diego, San Diego, CA
Background/Purpose: Rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) have joint-specific epigenetic and transcriptome profiles. This is particularly notable for homeobox (HOX) genes, which contribute to joint…
Abstract Number: 0624 • ACR Convergence 2022
CD20+ T Cells in the Synovial Fluid of Patients with Rheumatoid Arthritis Suggest a Role for Trogocytosis in Disease Pathogenesis and Activity
Maria De Santis¹, Natasa Isailovic², Giacomo Maria Guidelli³, Daniela Renna⁴, Arianna Sonaglia³, Nicoletta Luciano³, Marta Caprioli⁵, Angela Ceribelli¹, Francesca Motta⁶, Matteo Vecellio¹, Enrico Brunetta³ and Carlo Selmi¹, ¹Humanitas University, IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Pieve Emanuele, Italy, ²IRCCS Humanitas Research Hospital, Rozzano (MI), Italy, Rozzano, Italy, ³IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Rozzano, Italy, ⁴IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Milano, Italy, ⁵IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Pavia, Italy, ⁶Humanitas University, IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Rozzano, Italy
Background/Purpose: Approximately 1-2% of peripheral blood T cells express CD20, a marker of the B lineage, in both healthy individuals and patients with rheumatoid arthritis…
Abstract Number: 0754 • ACR Convergence 2022
Persistent but Disturbed Germinal Center Reaction Among 3rd SARS-CoV-2 Vaccination After Rituximab Exposure
Ana-Luisa Stefanski¹, Hector Rincon-Arevalo¹, Eva Schrezenmeier², Franziska Szelinski¹, Jacob Ritter³, Yidan Chen¹, Christian Meisel⁴, Hubert Schrezenmeier⁵, Andreia C. Lino⁶ and Thomas Dörner¹, ¹Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, ²Department of Nephrology and Medical Intensive Care, Charité Universitätsmedizin Berlin; DRFZ Berlin; Berlin Institute of Health Charité Universitätsmedizin Berlin, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Berlin Institute of Health Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Department of Medical Immunology, Charité University Medicine and Labor Berlin-Charité Vivantes, Berlin, Germany, ⁵Institute of Transfusion Medicine, Ulm University, Ulm, Germany and Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Württemberg – Hessen and University Hospital Ulm, Ulm, Germany, ⁶Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany
Background/Purpose: Durable vaccine-mediated immunity relies on the generation of long-lived plasma cells and memory B cells (MBCs), differentiating upon germinal center (GC) reactions. SARS-CoV-2 mRNA…
Abstract Number: 0814 • ACR Convergence 2022
Clinical Correlation of Dense Fine Speckled (DFS) Pattern of ANA
Smarika Sapkota¹, Jerry Molitor², michael evans², Benjamin Kofoed³, Adam Lord³, Londyn Robinson³ and John crosson², ¹University of Colorado, Aurora, CO, ²University of Minnesota, Minneapolis, MN, ³University of Minnesota Medical School, Minneapolis, MN
Background/Purpose: The clinical significance of Dense Fine Speckled (DFS) pattern Anti-nuclear antibodies (ANA) by indirect immunofluorescence method (IIF) is unclear and has been inversely associated…
Abstract Number: 0896 • ACR Convergence 2022
Screening of Lipids in Patients with Rheumatoid Arthritis: Academic Rheumatology Practice Quality Improvement Analysis
Sukhraj Singh¹ and Gurjit S. Kaeley², ¹University of Florida-Jacksonville, Jacksonville, FL, ²UF COM-J, Ponte Vedra Beach, FL
Background/Purpose: Patients with Rheumatoid Arthritis (RA) have 50% increased risk of cardiovascular disease (CVD) mortality compared with the general population. The American College of Cardiology/American…
Abstract Number: 0912 • ACR Convergence 2022
Associations Between Fatty Acid Amide Hydrolase Variants and Response to Cannabis Use for Pain Management in Rheumatoid Arthritis
Kristin Wipfler¹, Joanna Zeiger², Teresa Simon³, Stuart Kassan⁴ and Kaleb Michaud⁵, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²Canna Research Foundation, Boulder, CO, ³Physicians Research Center Consultant to ForWard, Toms River, NJ, ⁴Colorado Arthritis Associates, Lakewood, CO, ⁵University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Fatty acid amide hydrolase (FAAH) is a serine hydrolase that breaks down the endocannabinoid/cannabinoid receptor agonist anandamide. Variants in the FAAH gene have been…
Abstract Number: 0928 • ACR Convergence 2022
Use of Disease Modifying Anti-rheumatic Drugs and Risk of Multiple Myeloma in US Veterans with Rheumatoid Arthritis
Namrata Singh¹, Alexander Peterson², Aaron Baraff², Sarah Chung³, David Coffey⁴, Bryant England⁵, Pankti Reid⁶, Joshua Baker⁷, Jennifer Barton⁸, Nicholas Smith⁹, Ted Mikuls¹⁰ and Noel Weiss³, ¹University of Washington, Bellevue, WA, ²VA Puget Sound, SEATTLE, WA, ³University of Washington, Seattle, WA, ⁴University of Miami, Miami, FL, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶University of Chicago Medical Center, Chicago, IL, ⁷University of Pennsylvania, Philadelphia, PA, ⁸VA Portland Health Care System/OHSU, Portland, OR, ⁹VA Puget Sound/University of Washington, Seattle, WA, ¹⁰Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Biologic (b) and targeted synthetic (ts) DMARDs used in the management of rheumatoid arthritis (RA) target inflammatory pathways implicated in the pathogenesis of multiple…
Abstract Number: 1098 • ACR Convergence 2022
Perceived Barriers and Opportunities to Accessing Rheumatoid Arthritis Care on Navajo Nation: The Primary Care Providers’ Perspectives
Jennifer Mandal¹, Catherine Nasrallah², Tabitha Carroway³, Mary Margaretten³, Gwendolyn Grant⁴ and Jinoos Yazdany³, ¹University of California San Francisco, San Francisco, CA, ²UCSF, San Francisco, ³UCSF, San Francisco, CA, ⁴Centura Health, Durango, CO
Background/Purpose: Navajo Nation is the largest American Indian reservation, home to 250,000 tribal members living on 27,000 square miles. The prevalence of RA among the…
Abstract Number: 1211 • ACR Convergence 2022
Impact of Change in Biologic Disease Modifying Antirheumatic Drug Therapy on Disease Activity Measures: Findings from a Large Contemporaneous Real-World Longitudinal Database of RA Patients
Zhaohui Su¹, Lauren Stevens², Tom Brecht¹, Jessica Paulus¹ and Stefan Weiss³, ¹OM1, Inc., Boston, MA, ²OM1, Inc., Lexington, KY, ³OM1, Inc., Chapel Hill, NC
Background/Purpose: While many clinical trials provide direct comparisons between biologic disease modifying antirheumatic drugs (bDMARD) and nonbiologic DMARDs (nDMARD), there is a need to better…
Abstract Number: 1339 • ACR Convergence 2022
Impact of the COVID-19 Pandemic on Patients with Rheumatoid Arthritis: Data from the Ontario Best Practices Research Initiative (OBRI)
Matthew Wong-Pack¹, Elliot Hepworth², Mohammad Movahedi³, Bindee Kuriya¹, Janet Pope⁴, Edward Keystone⁵, Carter Thorne⁶, VANDANA AHLUWALIA⁷, Angela Cesta⁸, Carol Mously⁸, Claire Bombardier¹, Arthur Lau⁹ and Sibel Aydin¹⁰, ¹University of Toronto, Toronto, ON, Canada, ²University of Ottawa, Ottawa, ON, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁶Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷William Osler Health System, Brampton, ON, Canada, ⁸University Health Network, Toronto, ON, Canada, ⁹McMaster University, Hamilton, ON, Canada, ¹⁰University of Ottawa, Rheumatology, Ottawa, Canada, Ottawa, ON, Canada
Background/Purpose: The COVID-19 Pandemic created challenges for patients with rheumatoid arthritis (RA), including accessing the health care system, transition to unplanned virtual care, reduction in…
Abstract Number: 1396 • ACR Convergence 2022
Risk of Hospitalized Infections in Older Elderly Rheumatoid Arthritis Patients Treated with Biological/Targeted Synthetic DMARDs: Evaluation Using Data from a Japanese Claims Database
Masayoshi Harigai¹, Takao Fujii², Ryoko Sakai³, Ataru Igarashi⁴, Ayako Shoji⁵, Hiroko Yamaguchi⁶, Katsuhiko Iwasaki⁶, Misako Makishima⁷, Amika Yoshida⁷, Norihiro Okada⁷, Katsuhisa Yamashita⁷ and Yutaka Kawahito⁸, ¹Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ²Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan, ³Department of Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan, ⁴Department of Health Economics & Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan; Unit of Public Health and Preventive Medicine, Yokohama City University of Medicine, Kanagawa, Japan, ⁵Medilead Inc., Tokyo, Japan; Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan; Healthcare Consulting Inc., Tokyo, Japan, Shinjuku-ku, Japan, ⁶Medilead Inc., Tokyo, Japan, Shinjuku-ku, Japan, ⁷Chugai Pharmaceutical Co., Ltd., Chuo-ku, Tokyo, Japan, ⁸Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, Kyoto, Kyoto, Japan
Background/Purpose: Safety evidence of biological or targeted synthetic DMARDs (b/tsDMARDs) is still insufficient in older elderly ( >=75 years old (y/o)) patients with rheumatoid arthritis…
Abstract Number: 1412 • ACR Convergence 2022
Coronary Microvascular Dysfunction in Patients with Rheumatoid Arthritis and Diabetes Mellitus: A Cross-sectional Study with 13NH3 Myocardial PET/CT
Bas Dijkshoorn¹, Remco Knol², Friso Van Der Zant², Michael Nurmohamed³ and Suat Simsek², ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²Noord-west Ziekenhuis groep, Alkmaar, Netherlands, ³Amsterdam University Medical Center, Kortenhoef, Netherlands
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular disease. This risk is similar to that of diabetes mellitus (DM). There have…
Abstract Number: 1431 • ACR Convergence 2022
Impact of Tofacitinib on Fracture Risk in Rheumatoid Arthritis
Karen E Hansen¹, Mahta Mortezavi², Edward Nagy³, Cunshan Wang⁴, Carol A Connell⁴, Zaher Radi⁵, Heather J Litman⁶, Giovanni Adami⁷ and Maurizio Rossini⁷, ¹Rheumatology Division, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Pfizer Inc, New York, NY, ³Pfizer Ltd, Tadworth, United Kingdom, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc., Cambridge, MA, ⁶CorEvitas, LLC, Waltham, MA, ⁷Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy
Background/Purpose: Preclinical data suggest that tofacitinib stimulates osteoblast function and would have a protective effect on bone health and fracture risk in RA.1 We report…
Abstract Number: 1606 • ACR Convergence 2022
An Expanded Anti-citrullinated Protein Antibody Profile Derived Using Unsupervised Machine Learning Predicts Treatment Responses to Biologic Therapies in Rheumatoid Arthritis
nozima Aripova¹, George Reed², Bryant England¹, William Robinson³, Dimitrios Pappas⁴, Joel Kremer⁵, Geoffrey Thiele¹ and Ted Mikuls⁶, ¹University of Nebraska Medical Center, Omaha, NE, ²The Corrona Research Foundation and University of Massachusetts, Albany, NY, ³Stanford University School of Medicine, Palo Alto, CA, ⁴CorEvitas, LLC, Waltham, MA, ⁵The Corrona Research Foundation, Delray Beach, FL, ⁶Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA) treatments have advanced with the availability of biologic therapies. Despite these advances, 30-40% of patients receiving a biologic do not adequately…
Abstract Number: 1728 • ACR Convergence 2022
Increased Frequency of Highly Differentiated T Effector Memory Cells Re-expressing CD45RA (Temra) and Cytomegalovirus Seropositivity Are Associated with Persistent Disease Specifically Refractory to Anti-TNF Therapy in Rheumatoid Arthritis
Su-Ann Yeoh, James Kimpton, Muhammad Shipa, Eleanor Hawkins, Arne Akbar and Michael Ehrenstein, University College London, London, United Kingdom
Background/Purpose: Enrichment of highly differentiated T cells have been reported in rheumatoid arthritis (RA) patients compared to healthy individuals. The role of highly differentiated T…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].